

GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED / YEAR ENDED 30.09.2016

Rs. In Lacs

Particulars	Quarter Ended 30.09.16 Unaudited	Quarter Ended 30.06.16 Unaudited	Quarter Ended 30.09.15 Unaudited	For the Period Ended 30.09.16 Unaudited	For the Period Ended 30.09.15 Unaudited	For the Year Ended 31.03.16 Unaudited
INCOME:						
Net Sales / Income from Operations (Net of Excise Duty)	6429.25	5536.25	5130.73	11965.50	8889.93	20205.16
Other Operating Income	9.61	9.12	10.85	18.73	19.25	26.61
Total Income from Operations (Net)	6438.86	5545.37	5141.58	11984.23	8909.18	20231.77
EXPENSES:						
Cost of Materials Consumed	2465.17	1542.58	2044.78	4007.75	3800.77	7626.31
Purchase of Stock-in-Trade	1057.16	1127.51	786.09	2184.67	1343.38	4280.95
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(234.48)	(102.88)	(220.69)	(337.36)	(901.33)	(1709.85)
Employee Benefits Expenses	1001.26	1002.30	846.15	2003.56	1591.96	3197.53
Depreciation and Amortisation Expenses	93.68	91.12	94.56	184.80	186.92	378.68
Other Expenses	1498.30	1338.74	1240.56	2837.04	2263.60	4856.12
Total Expenses	5881.09	4999.37	4791.45	10880.46	8285.30	18629.74
Profit from Operations before Other Income, finance costs and Exceptional Items	557.77	546.00	350.13	1103.77	623.88	1602.03
Other Income	5.89	5.95	33.36	11.84	35.34	54.24
Profit from ordinary activities before finance costs and exceptional items	563.66	551.95	383.49	1115.61	659.22	1656.27
Finance Costs	141.41	136.91	122.80	278.32	237.53	536.84
Profit from ordinary activities after finance costs but before exceptional items	422.25	415.04	260.69	837.29	421.69	1119.43
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	422.25	415.04	260.69	837.29	421.69	1119.43
Current Tax	157.50	185.50	112.20	343.00	187.20	429.30
Deferred Tax	1.04	(25.71)	(16.60)	(24.67)	(34.63)	(42.63)
Short/(Excess) Tax Provisions of Earlier Years	0.00	0.00	0.00	0.00	0.00	0.34
Net Profit from Ordinary Activities After Tax	263.71	255.25	165.09	518.96	269.12	732.42
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	263.71	255.25	165.09	518.96	269.12	732.42
Paid up Equity Share Capital (Face Value of Rs 1/- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	1204.84	1936.49	2040.52	3141.33	2205.61	2622.37
E.P.S	0.34	0.33	0.21	0.67	0.35	0.95
Public Shareholding						
-- Number of Shares of Rs 1/- Each	23222355	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding						
a) Pledged / Encumbered						
-- Number of Shares of Rs 1/- Each	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Sharesholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered						
-- Number of Shares of Rs 1/- Each	54127645	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Sharesholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%



GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER / ENDED 30.09.2016						Rs. In Lacs
Particulars	Quarter Ended 30.09.16 Unaudited	Quarter Ended 30.06.16 Unaudited	Quarter Ended 30.09.15 Unaudited	For the Period Ended 30.09.16 Unaudited	For the Period Ended 30.09.15 Unaudited	For the Year Ended 31.03.16 Unaudited
SEGMENT REVENUE						
Sales & Service						
Pharma	6134.29	5510.15	5040.12	11644.44	8690.34	19769.64
Consumer	294.96	26.10	90.16	321.06	199.59	435.52
Total	6429.25	5536.25	5130.28	11965.50	8889.93	20205.16
Unallocabel Income	15.50	15.07	44.21	30.57	54.59	80.85
Total Segment Revenue	6444.75	5551.32	5174.49	11996.07	8944.52	20286.01
SEGMENT RESULTS						
Pharma	1488.71	1252.15	970.22	2740.86	1691.14	4110.06
Consumer	30.39	2.38	10.41	32.77	22.45	42.18
TOTAL	1519.10	1254.53	980.63	2773.63	1713.59	4152.24
Less: Unallocated over heads	837.09	611.46	502.58	1448.55	867.46	2117.28
Finance Charges	141.41	136.91	122.80	278.32	237.53	536.84
Depreciation	93.68	91.12	94.56	184.80	186.92	378.68
Tax provision	183.21	159.79	95.60	343.00	152.57	387.01
Net Profit after Tax	263.71	255.26	165.09	518.96	269.12	732.42




AUDITED STATEMENT OF ASSETS AND LIABILITIES			
Particulars	AS AT 30.09.2016 Audited	AS AT 30.09.2015 Audited	AS AT 31.03.2016 Audited
EQUITY AND LIABILITIES			
Shareholder's Funds			
a) Share Capital	773.50	773.50	773.50
b) Reserves and Surplus	3,141.33	2,205.61	2,622.37
Sub-total - Shareholder's Funds	3914.83	2979.11	3395.87
Non-current liabilities			
a) Long-term borrowings	543.54	819.20	772.02
b) Deferred tax liabilities (Net)	87.44	120.10	112.11
c) Other long-term liabilities	127.27	466.82	438.87
d) Long-term provisions	213.07	147.86	139.05
Sub-total - Non-current liabilities	971.32	1553.98	1462.05
Current liabilities			
a) Short-term borrowings	3,665.20	2,707.46	3,228.20
b) Trade payables	6,714.63	5,752.77	5,262.24
c) Other current liabilities	1,883.11	1,586.37	1,404.35
d) Short-term provisions	750.10	448.59	467.20
Sub-total - Current liabilities	13013.04	10495.19	10361.99
TOTAL - EQUITY AND LIABILITIES	17899.19	15028.28	15219.91
ASSETS			
Non-current assets			
a) Fixed assets	2,138.46	2,367.75	2,214.67
b) Non-current investments	0.93	0.93	0.93
c) Long-term loans and advances	706.45	804.15	729.93
d) Other non-current assets	211.65	395.89	309.49
Sub-total - Non-Current assets	3057.49	3568.72	3255.02
Current assets			
a) Current investments			
b) Inventories	5,823.69	4,901.65	5,026.31
c) Trade receivables	7,523.01	4,651.75	5,622.80
d) Cash and cash equivalents	389.69	564.62	615.89
e) Short-term loans and advances	1,105.31	1,341.54	699.89
f) Other current assets			
Sub-total - Current assets	14841.70	11459.56	11964.89
TOTAL - ASSETS	17899.19	15028.28	15219.91

Notes forming part of the audited financial results for the quarter ended September 30, 2016

- The above financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on November 14, 2016.
- For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2016.
- The figures of the quarter ended september 30, 2016 are the balancing figures between unaudited figures in respect of the period ended september 30, 2016 and the unaudited published year – to – date figures upto June 30, 2016 which were subject to limited review.
- Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on September 30, 2016: Nil.
- Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board
Gufic Biosciences Limited



Hemal M Desai
Chief Financial Officer & Whole Time Director
DIN 07014744

Mumbai Dated November 14, 2016

